Composition: each vial contains:

active substance:vincristine sulfate – 0.5 mg (1 ml vial) or 1 mg (2 ml vial).

Therapeutic indications

    –    Leukemia, including acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.

    –    Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphoma.

    –    Multiple myeloma.

    –    Solid tumors, including breast cancer, small cell lung cancer, head and neck tumors and soft tissue sarcoma.

    –    Solid tumors of children, including Ewing's sarcoma, embryonic rhabdomyosarcoma, neuroblastoma, Wilms tumor, retinoblastoma and medulloblastoma.

Idiopathic thrombocytopenic purpura (with resistance to corticosteroids and ineffectiveness of splenectomy). It is not recommended to use vincristine as a first-line preparation. The recommended weekly doses of vincristine from 3 to 4 weeks in some patients led to a stable remission. If the patient does not respond to vincristine after 3 to 6 doses, then the probability of positive dynamics for additional doses is small.


АТС code


Pharmaceutical form

solution for injection 1 mg/2 ml

Storage conditions

Store in protected from light place at temperature between 2°C and 8°C.